Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.40)
# 322
Out of 5,152 analysts
240
Total ratings
44.24%
Success rate
26.57%
Average return
Main Sectors:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Upgrades: Neutral | $55 → $9 | $10.65 | -15.49% | 11 | Mar 2, 2026 | |
| IRON Disc Medicine | Maintains: Overweight | $153 → $125 | $60.34 | +107.16% | 10 | Feb 17, 2026 | |
| EPRX Eupraxia Pharmaceuticals | Maintains: Overweight | $11 → $19 | $7.96 | +138.69% | 2 | Jan 15, 2026 | |
| FOLD Amicus Therapeutics | Downgrades: Neutral | $21 → $15 | $14.33 | +1.19% | 8 | Dec 19, 2025 | |
| DBVT DBV Technologies | Maintains: Overweight | $42 → $48 | $22.08 | +117.39% | 2 | Dec 17, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Overweight | $15 → $24 | $8.16 | +194.12% | 5 | Dec 8, 2025 | |
| LXEO Lexeo Therapeutics | Initiates: Overweight | $19 | $6.77 | +180.65% | 2 | Dec 1, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Overweight | $29 → $24 | $8.79 | +173.04% | 4 | Nov 6, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $32 → $38 | $29.50 | +28.81% | 9 | Nov 5, 2025 | |
| SUPN Supernus Pharmaceuticals | Maintains: Overweight | $46 → $63 | $54.27 | +16.09% | 4 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $105 | $21.46 | +389.28% | 20 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $118 | $63.20 | +86.71% | 21 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $74 | $56.20 | +31.67% | 2 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $16 | $5.61 | +185.20% | 1 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $25.82 | +16.19% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $163 → $81 | $16.23 | +399.08% | 16 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $4.49 | +55.90% | 16 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $67 → $123 | $38.57 | +218.90% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $3.70 | +2,332.43% | 4 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $0.39 | +1,690.28% | 10 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $15.70 | +59.24% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $29.36 | +128.20% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $4.26 | +299.06% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $2.77 | +188.81% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $1.26 | +773.02% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $4.87 | +269.61% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $0.74 | +1,797.02% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $1.09 | +1,092.66% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.18 | +1,679.66% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.84 | +226.09% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $0.43 | +4,531.77% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $7.12 | +223.03% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $0.95 | +94,706.70% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $400 | $28.36 | +1,310.44% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $2.64 | +3,119.70% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $6.53 | +2,656.51% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $1.83 | +9,763.01% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $1.74 | +532.18% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.39 | +4,216.55% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $0.79 | +11,344.56% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $0.63 | +399,900.00% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3,040 | $5.75 | +52,769.57% | 1 | Jan 9, 2020 |
uniQure
Mar 2, 2026
Upgrades: Neutral
Price Target: $55 → $9
Current: $10.65
Upside: -15.49%
Disc Medicine
Feb 17, 2026
Maintains: Overweight
Price Target: $153 → $125
Current: $60.34
Upside: +107.16%
Eupraxia Pharmaceuticals
Jan 15, 2026
Maintains: Overweight
Price Target: $11 → $19
Current: $7.96
Upside: +138.69%
Amicus Therapeutics
Dec 19, 2025
Downgrades: Neutral
Price Target: $21 → $15
Current: $14.33
Upside: +1.19%
DBV Technologies
Dec 17, 2025
Maintains: Overweight
Price Target: $42 → $48
Current: $22.08
Upside: +117.39%
Fulcrum Therapeutics
Dec 8, 2025
Maintains: Overweight
Price Target: $15 → $24
Current: $8.16
Upside: +194.12%
Lexeo Therapeutics
Dec 1, 2025
Initiates: Overweight
Price Target: $19
Current: $6.77
Upside: +180.65%
Zevra Therapeutics
Nov 6, 2025
Maintains: Overweight
Price Target: $29 → $24
Current: $8.79
Upside: +173.04%
Rigel Pharmaceuticals
Nov 5, 2025
Maintains: Neutral
Price Target: $32 → $38
Current: $29.50
Upside: +28.81%
Supernus Pharmaceuticals
Sep 30, 2025
Maintains: Overweight
Price Target: $46 → $63
Current: $54.27
Upside: +16.09%
Sep 5, 2025
Reiterates: Overweight
Price Target: $105
Current: $21.46
Upside: +389.28%
Sep 3, 2025
Reiterates: Overweight
Price Target: $118
Current: $63.20
Upside: +86.71%
Aug 27, 2025
Reiterates: Overweight
Price Target: $74
Current: $56.20
Upside: +31.67%
May 22, 2025
Assumes: Overweight
Price Target: $16
Current: $5.61
Upside: +185.20%
May 14, 2025
Reiterates: Overweight
Price Target: $30
Current: $25.82
Upside: +16.19%
May 7, 2025
Maintains: Overweight
Price Target: $163 → $81
Current: $16.23
Upside: +399.08%
Apr 28, 2025
Reiterates: Overweight
Price Target: $7
Current: $4.49
Upside: +55.90%
Mar 27, 2025
Maintains: Overweight
Price Target: $67 → $123
Current: $38.57
Upside: +218.90%
Mar 26, 2025
Reiterates: Overweight
Price Target: $90
Current: $3.70
Upside: +2,332.43%
Mar 18, 2025
Reiterates: Overweight
Price Target: $7
Current: $0.39
Upside: +1,690.28%
Mar 4, 2025
Reiterates: Overweight
Price Target: $25
Current: $15.70
Upside: +59.24%
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $29.36
Upside: +128.20%
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $4.26
Upside: +299.06%
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $2.77
Upside: +188.81%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $1.26
Upside: +773.02%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $4.87
Upside: +269.61%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $0.74
Upside: +1,797.02%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $1.09
Upside: +1,092.66%
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.18
Upside: +1,679.66%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $1.84
Upside: +226.09%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $0.43
Upside: +4,531.77%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $7.12
Upside: +223.03%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $0.95
Upside: +94,706.70%
Mar 17, 2023
Initiates: Overweight
Price Target: $400
Current: $28.36
Upside: +1,310.44%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $2.64
Upside: +3,119.70%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $6.53
Upside: +2,656.51%
May 26, 2021
Initiates: Overweight
Price Target: $180
Current: $1.83
Upside: +9,763.01%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $1.74
Upside: +532.18%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $1.39
Upside: +4,216.55%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $0.79
Upside: +11,344.56%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $0.63
Upside: +399,900.00%
Jan 9, 2020
Initiates: Overweight
Price Target: $3,040
Current: $5.75
Upside: +52,769.57%